Table 2.
Outcomes | Absolute hs-cTNT change among all participants† | Relative change among persons with measurable hs-cTNT values‡ |
|||||
---|---|---|---|---|---|---|---|
Incident Detectable (Baseline <5ng/L, Follow-up ≥5ng/L) |
Incident Elevated (Baseline <14ng/L, Follow-up ≥14ng/L) |
>50% Decrease |
Change ≤50% |
>50% Increase |
|||
No (N=3888) |
Yes (N=2152) |
No (N=8155) |
Yes (N=443) |
(N=74) | (N=2227) | (N=1147) | |
Heart Failure | n=235 | n=260 | n=761 | n=134 | n=10 | n=309 | n=234 |
Incidence Rate | 4.5 | 9.7 | 7.2 | 30.5 | 10.7 | 11.1 | 18.0 |
Demographic Model* |
1 (ref) | 2.05 (1.70–2.47) |
1 (ref) | 3.88 (3.20–4.71) |
1.06 (0.57–2.00) |
1 (ref) | 1.64 (1.39–1.95) |
Full Model* | 1 (ref) | 1.96 (1.62–2.37) |
1 (ref) | 2.78 (2.27–3.40) |
0.49 (0.23–1.01) |
1 (ref) | 1.60 (1.35–1.91) |
Coronary Heart Disease |
n=330 | n=301 | n=969 | n=119 | n=9 | n=374 | n=239 |
Incidence Rate | 6.4 | 11.6 | 9.4 | 28.3 | 10.0 | 13.9 | 19.1 |
Demographic Model* |
1 (ref) | 1.36 (1.15–1.61) |
1 (ref) | 2.09 (1.72–2.55) |
0.78 (0.40–1.52) |
1 (ref) | 1.31 (1.11–1.54) |
Full Model* | 1 (ref) | 1.38 (1.16–1.63) |
1 (ref) | 1.75 (1.43–2.15) |
0.47 (0.22–1.03) |
1 (ref) | 1.28 (1.09–1.52) |
Death | n=508 | n=486 | n=1496 | n=209 | n=17 | n=584 | n=392 |
Incidence Rate | 9.5 | 17.5 | 13.7 | 42.8 | 17.7 | 20.1 | 28.2 |
Demographic Model* |
1 (ref) | 1.45 (1.27–1.66) |
1 (ref) | 2.41 (2.08–2.80) |
1.00 (0.62–1.62) |
1 (ref) | 1.39 (1.22–1.58) |
Full Model* | 1 (ref) | 1.50 (1.31–1.72) |
1 (ref) | 2.10 (1.80–2.46) |
0.57 (0.33–0.99) |
1 (ref) | 1.39 (1.22–1.59) |
Demographic Model- Adjusted for age, sex, race-center; Full Model- Adjusted for age, sex, race-center, body mass index (kg/m3), C-reactive protein (mg/L), smoking (current; former; never), drinking (current; former; never), systolic blood pressure (mmHg), current use of blood pressure-lowering medication (yes or no), diagnosed diabetes (yes or no), LDL-cholesterol (mg/dL), HDL-cholesterol (mg/dL), triglycerides (mg/dL), and current use of cholesterol-lowering medication (yes or no), estimated GFR (mL/min/1.73m2), and left ventricular hypertrophy (yes or no, by Cornell criteria).
Absolute change categories are not mutually exclusive
Relative change sample (N=3448) only includes those who have measurable hs-cTnT values (≥3 ng/L) at both visits. Relative change is calculated as a percent of baseline hs-cTNT. The full model for this relative change exposure is further adjusted for visit 2 hs-cTNT.